Skip to main
VYNE
VYNE logo

Vyne Therapeutics (VYNE) Stock Forecast & Price Target

Vyne Therapeutics (VYNE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VYNE Therapeutics Inc. is showing promising clinical advancements, particularly with its product candidate VYN202, which demonstrated a four-point improvement in joint pain and a significant 48% reduction in serum C-reactive protein among treated patients, indicating effective management of immuno-inflammatory conditions. The company's financial stability is emphasized by the maintenance of approximately $40 million in cash, which provides the necessary liquidity to support ongoing operations and strategic development initiatives. These factors, combined with the encouraging data from ongoing trials, contribute to a positive outlook for the company's stock performance.

Bears say

VYNE Therapeutics Inc. has encountered significant challenges, as evidenced by its recent Phase 2b trial results, which failed to meet the primary endpoint for vitiligo and revealed a concerningly high vehicle effect coupled with an elevated dropout rate among participants. The company's decision to discontinue treatment in the ongoing extension phase of the trial and terminate the Phase 2b trial indicates a substantial setback in its development pipeline. This series of events has prompted a downgrade of VYNE's stock rating, highlighting increased uncertainty surrounding the company's ability to advance its immuno-inflammatory therapies successfully.

Vyne Therapeutics (VYNE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vyne Therapeutics (VYNE) Forecast

Analysts have given Vyne Therapeutics (VYNE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Vyne Therapeutics (VYNE) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vyne Therapeutics (VYNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.